Belite Bio Receives Sakigake (Pioneer Drug) Designation of
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and ...
Read more
ADVERTISEMENT
ADVERTISEMENT
Tag: belite
Belite Bio Reports First-Quarter 2024 Financial Results and
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and ...
Read moreBelite Bio Announces $25 Million Registered Direct
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage ...
Read moreBelite Bio Announces Availability of Annual Report on Form
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused ...
Read moreBelite Bio Reports Fourth Quarter and Full Year 2023
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and ...
Read moreBelite Bio Reports Third Quarter 2023 Operational
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across ...
Read more
LifeCare News is a registered magazine in RNI (Registrar of Newspapers for India) is started in 2015, as well as Lifecarenews have a malti language portal. Life Care News portal was connected with many reputed news agency.